RxSight Inc.
RXST | NASDAQ
$5.14
-$0.06 (-1.15%)
At close: Sep 21, 2026, 4:00 PM ET
$5.06
-$0.08 (-1.56%)
Pre-market:
Sep 22, 2026, 7:35 AM ET
Company Profile
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Key Executives
| Name | Position |
|---|---|
| Aziz Mottiwala | President, Chief Executive Officer & Director |
| Ilya Goldshleger | Chief Operating Officer |
| Mark Wilterding | Chief Financial Officer |
| Adam Dashe | Executive Vice President of International |
| Eric J. Weinberg | Chief Business Development Officer |
| Jim Schindler | Executive VP & General Counsel |
| Maureen O'Connell | Executive Vice President of Clinical & Regulatory Affairs |
| Oliver Moravcevic | Vice President of Investor Relations |
| Patrick Cullen | Executive Vice President of Quality & Infrastructure Operations |
| Ronald Kurtz | Chief Medical Officer |
| Trent Campbell | Executive VP of US Sales & Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Aug 25, 2026 | SC TO-I/A | [Amend] Filing |
| Aug 19, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 10, 2026 | SC TO-I | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 04, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
RxSight Inc.
| Country | United States |
| IPO Date | Jul 29, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 461 |
| CEO | Aziz Mottiwala |
Contact Details
100 Columbia Aliso Viejo,
California 92656 United States
Stock Details
| Ticker Symbol | RXST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001111485 |
| CUSIP Number | 78349D107 |
| ISIN Number | US78349D1072 |
| SIC Code | 3851 |
Add to Watchlist
Select watchlists to add or remove RXST